EVANSTON, IL–(BUSINESS WIRE)–ZS, a global management consulting and technology company, today announced the expansion of ZAIDYN.®a life sciences intelligence platform powered by agent AI. This expansion introduces ZAIDYN Medical™ and ZAIDYN Content™. These are two new purpose-built modular application suites that combine deep domain expertise with data, advanced analytics, and AI to address specific business challenges. These releases reflect ZS’ leadership in applying agent AI to regulated, high-stakes workflows, helping life sciences organizations accelerate decision-making and support execution with the governance, scientific rigor, and compliance that the industry demands.
ZAIDYN operationalizes decision-ready intelligence securely and at scale, and embeds it into the way teams work. ZAIDYN has dedicated agents that monitor signals, recommend next-best actions, and run managed workflows with human review, approval, and overrides at each step. Built on the foundation of ZAIDYN Commercial, ZAIDYN Medical, and ZAIDYN Content, it embeds agenttic AI into medical intelligence and compliant content supply chains through a shared intelligence layer, enabling leaders to act faster, more confidently, and more consistently.
“ZS has been helping life sciences teams solve the most complex commercial and medical challenges for decades, and now we are packaging that expertise into products using agent AI,” said Sunil Dixit, chief product officer at ZS. “We built these new product lines to address the pressure on life sciences organizations to do more with less. Armed with domain-based and ontology-rich agents, our agents can support and streamline medical, legal, and regulatory (MLR) review workflows and provide insights to medical affairs teams to accelerate the speed of their work.”
Zaidin Medical
ZAIDYN Medical is supported by ZS’ extensive innovation and intellectual property portfolio, including issued and pending U.S. patents focused on AI-driven medical intelligence. The ZAIDYN OLI™ suite includes features related to technologies described in recently granted U.S. patents, highlighting ZS’ innovation in AI-driven opinion leadership and impactful network intelligence for life sciences.
ZAIDYN Medical helps medical affairs teams identify, prioritize, and engage key opinion leaders while generating end-to-end insights 50-70% faster. The platform also includes features that help teams identify gaps in care, measure patient outcomes, generate scientific and stakeholder insights, and support compliant healthcare practices.
“Medical teams are under increasing pressure to focus their time and attention where it matters most,” said Murali Gopal, MD, senior vice president and medical affairs director at Ardelyx. “Approaches that help teams prioritize stakeholders and more effectively prepare for scientific endeavors can support more focused conversations and increased continuity across interactions.”
Zaidin content
ZAIDYN Content is a purpose-built, flexible agent AI suite designed to accelerate the supply chain from life sciences content creation to MLR approval and reuse. The Content MLR Accelerator module embeds compliance, brand, and medical intelligence directly into review workflows, enabling teams to improve submission readiness, streamline reviews, and scale compliant content reuse and localization without increasing risk.
ZAIDYN Content also supports content generation and personalization, enabling faster reuse of compliant content across brands, markets, and languages. ZAIDYN Content has been deployed at enterprise scale to accelerate over 100,000 assets across brands, markets, and languages, reducing cycle times for personalized and derived content by over 67%.
“The true value of innovation in life sciences is realized when it reaches the people who need it,” said ZS Chairman Jaydeep Bajaj. “ZAIDYN content helps organizations quickly deliver critical information to patients, healthcare providers, and stakeholders, supporting meaningful impact for everyone.”
Additional information about ZAIDYN is available at ZAIDYN.ai.
